Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$77.75 USD

77.75
2,585,851

+1.08 (1.41%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $77.76 +0.01 (0.01%) 7:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Arpita Dutt headshot

Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More

by Arpita Dutt

Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.

    AstraZeneca (AZN) Beats on Q2 Earnings, Falls on Failed Study

    by Zacks Equity Research

    AstraZeneca PLC (AZN) reported second-quarter 2017 core earnings of 87 cents per ADS, which beat the Zacks Consensus Estimate of 41 cents. Failure in lung cancer study on Imfinzi however pulled the stock down.

      Merck (MRK) Beats on Q2 Earnings and Sales, Keeps 2017 View

      by Zacks Equity Research

      Merck & Co., Inc. (MRK) beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda.

        Ironwood (IRWD) Reports Positive Data on Reflux Candidate

        by Zacks Equity Research

        Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.

          Arpita Dutt headshot

          Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

          by Arpita Dutt

          Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

            AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

            by Zacks Equity Research

            AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

              Arena Announces Secondary Stock Worth $150M (revised)

              by Zacks Equity Research

              Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.

                Pfizer Xeljanz Label Expansion Application Accepted by FDA

                by Zacks Equity Research

                Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.

                  J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

                  by Zacks Equity Research

                  Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.

                    Arpita Dutt headshot

                    Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.

                    by Arpita Dutt

                    Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.

                      Clovis (CLVS) Focuses on Rubraca Launch and Label Expansion

                      by Zacks Equity Research

                      We issued an updated research report on Boulder, CO-based Clovis Oncology, Inc. (CLVS) on Jul 12.

                        Lilly Settles Patent Litigation on Cialis with Generic Firms

                        by Zacks Equity Research

                        Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).

                          Mallinckrodt to Pay $35M for Controlled Substances Probe

                          by Zacks Equity Research

                          Mallinckrodt plc (MNK) recently finalized the agreement which it had reached with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys' Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York.

                            Arena Announces Secondary Stock Offering of 150M Shares

                            by Zacks Equity Research

                            Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.

                              BioLineRx/Roche Scan BL-8040-Tecentriq for Pancreatic Cancer

                              by Zacks Equity Research

                              BioLineRx Ltd. (BLRX) announced that its partner Genentech, has initiated a phase Ib/II study, evaluating BL-8040 in combination Tecentriq (atezolizumab) for treatment of patients with metastatic pancreatic ductal adenocarcinoma.

                                Ryan McQueeney headshot

                                3 Large Cap Pharma Stocks to Buy Now

                                by Ryan McQueeney

                                The healthcare sector has dominated headlines this year thanks to promises from the GOP and the Trump administration related to repealing and replacing Obamacare. This uncertainty has not led to weak trading, and large cap pharma stocks have been among some of the biggest gainers this year. Check out these three large cap pharma stocks to buy now!

                                  Lilly's Breast Cancer Drug Gets Priority Review Status by FDA

                                  by Zacks Equity Research

                                  Eli Lilly and Company (LLY) announced that its new drug application for its pipeline candidate, abemaciclib , has been accepted for priority review by the FDA for patients with advanced breast cancer.

                                    Sanofi to Buy Vaccine Biotech Protein Sciences for $650M

                                    by Zacks Equity Research

                                    Sanofi (SNY), on Monday, announced plans to buy a Meriden, CT-based private vaccine biotech, Protein Sciences for an upfront payment of $650 million.

                                      Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff

                                      by Zacks Equity Research

                                      Both stocks carry a Zacks Rank #2 (Buy).

                                        Arpita Dutt headshot

                                        Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises

                                        by Arpita Dutt

                                        Merck's (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.

                                          Robust 1H for Pharma/Biotech Sector, 3 Big Stocks to Buy

                                          by Zacks Equity Research

                                          The pharma and biotech industry has been blessed with good health in the first half of the year.

                                            AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use

                                            by Zacks Equity Research

                                            AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.

                                              Minerva On Track to Initiate Phase III Schizophrenia Study

                                              by Zacks Equity Research

                                              Minerva Neurosciences, Inc. (NERV) announced that it is on track to begin phase III studies on its key schizophrenia pipeline candidate MIN-101 in the second half of this year, as planned.

                                                Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion

                                                by Zacks Equity Research

                                                Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.

                                                  5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017

                                                  by Zacks Equity Research

                                                  London-based pharma giant, AstraZeneca plc (AZN) has a strong product portfolio and is one of the key players in the global cardiovascular market.